Simvastatin reduces endothelial activation and damage but is partially ineffective in inducing endothelial repair in systemic sclerosis.

Nicoletta Del Papa(University of Milan), Agostino Cortelezzi(Istituti di Ricovero e Cura a Carattere Scientifico), Michela Cortiana(University of Milan), Tiziano Lucchi(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), D.P. Comina(University of Milan), Wanda Maglione(University of Milan), Claudio Vitali, Ilaria Silvestris(University of Milan)

PubMed

July 1, 2008

Cited by 47

Related Papers

Autologous Hematopoietic Stem Cell Transplantation vs Intravenous Pulse Cyclophosphamide in Diffuse Cutaneous Systemic Sclerosis

|JAMA|2014|739

Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL)

|Blood|2009|433

Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non–High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial

|Journal of Clinical Oncology|2016|394

Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients

|Blood|2014|373

Endothelial cells as target for antiphospholipid antibodies. Human Polyclonal and Monoclonal Anti‐β<sub>2</sub>‐Glycoprotein I Antibodies React In Vitro with Endothelial Cells Through Adherent β<sub>2</sub>‐Glycoprotein I and Induce Endothelial Activation

|Arthritis & Rheumatism|1997|290